Analyst William Plovanic of Canaccord Genuity maintained a Buy rating on Atricure (ATRC – Research Report), with a price target of $50.00.
William Plovanic’s Buy rating for AtriCure’s stock is predicated on several key considerations, including the company’s recent performance and forward-looking financial projections. Plovanic has highlighted AtriCure’s strong fourth-quarter revenue, which exceeded expectations with a 21% year-over-year increase. This performance is complemented by the company’s promising initial guidance for 2024, with projected revenues surpassing the estimates made by Canaccord Genuity. Furthermore, Plovanic recognizes AtriCure as a growth-oriented entity possessing a portfolio of unique products, such as Cryo Nerve Block and Hybrid AF therapies, which are expected to continue driving expansion and market impact.
The analyst’s confidence is further bolstered by AtriCure’s strategic clinical trials, including HEAL-IST and LeAAPS, and the potential market expansion through the Cryo Nerve Block. Plovanic also notes the importance of upcoming developments such as the impact of PFA on the market and the results of the CONVERGE trial, which could significantly influence investor sentiment. The company’s upward trajectory is not just limited to revenue; the guidance for adjusted EBITDA also suggests a positive outlook, with expectations of continuous annual improvement. These factors collectively substantiate Plovanic’s Buy rating, as they signal a strong growth trajectory and robust financial health for AtriCure.
According to TipRanks, Plovanic is an analyst with an average return of -1.4% and a 43.58% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as CVRx, Boston Scientific, and Atricure.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $60.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Atricure (ATRC) Company Description:
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
Read More on ATRC:
